CONTROL BIONICS ORD
Control Bionics Bolsters European Expansion with German Reimbursement for NeuroNode
Control Bionics (ASX: CBL) secures German reimbursement for NeuroNode, fueling Europe wholesale push and distributor ramp-up amid funding risks.
Control Bionics Signs US JV for iOS Speech Devices with NextLevel Assistive Technology
Control Bionics inks exclusive US JV with NextLevel for iOS speech devices, FDA Manufacturer of Record; aims 1,000–1,500 units/year in a USD 100–150m market.
Control Bionics Integrates Apple Brain–Computer Interface to Enhance Accessibility and Independence
Control Bionics (ASX: CBL) has implemented Apple’s new Brain–Computer Interface protocol across its product range, a major step forward in assistive communication technology for people living with severe speech and physical impairments.
Control Bionics’ US sales and revenue growth fuels strong start to FY25
Australian medical device company Control Bionics (ASX: CBL) is expecting US revenue for the first six months of the 2025 financial year to increase by more than 15% on the previous corresponding period. The anticipated performance reflects increasing demand for the company’s artificial intelligence-based solutions, growing market penetration and a new Healthcare Common Procedure Coding […]
